Back to Search
SAMIR UNDEVIA, M.D.
M.D.
Specialist
NPI: 1740228857IndividualAccepts Medicare
Specialties, Licenses & Credentials
SpecialistPrimary
Specialist
Code: 174400000X
036-102127(IL)
Education
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Class of 1997
Research & Publications (14)
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
PMID 18650079·Eur J Cancer·2008
3-trial
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
PMID 15520075·Ann Oncol·2004
3-trial
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
PMID 15292715·Invest New Drugs·2004
3-trial
Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
PMID 19577863·Int J Radiat Oncol Biol Phys·2010
8-other
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
PMID 19451436·J Clin Oncol·2009
3-trial
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
PMID 18425419·Invest New Drugs·2008
3-trial
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
PMID 18348295·Cancer·2008
3-trial
A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
PMID 17457044·Cancer Biol Ther·2007
3-trial
Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor.
PMID 16193390·J Neurooncol·2005
5-case
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
PMID 15536463·Clin Pharmacol Ther·2004
3-trial
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
PMID 15240529·Clin Cancer Res·2004
3-trial
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
PMID 15007088·J Clin Oncol·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 901 W WELLINGTON AVE
CHICAGO, IL 60657 - Phone
- (773) 296-5397
Quick Facts
- NPI
- 1740228857
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 14
Are you this provider?
Claim Your Profile